Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 4Phase 3 3Phase 1 2

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 47Squamous Cell Carcinoma of Head and Neck 30Head and Neck Neoplasms 17Colonic Neoplasms 15Rectal Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Carcinoma, Squamous Cell 4Recurrence 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Mouth Neoplasms 2Lung Neoplasms 2Laryngeal Diseases 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Tongue Neoplasms 1Stomach Neoplasms 1Rectal Diseases 1Radiation Injuries 1Precancerous Conditions 1Papillomavirus Infections 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, Follicular 1Intestinal Neoplasms 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Cetuximab × Clear all
NCT06064877 2026-04-09

FIERCE-HN

AVEO Pharmaceuticals, Inc.

Phase 3 Recruiting
410 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT01309126 2017-07-13

PRIMUS

HiberCell, Inc.

Phase 3 Terminated
217 enrolled
Gastrointestinal

Recurrence, Colorectal Neoplasms

NCT00095199 2012-10-15

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Eli Lilly and Company

Phase 3 Completed
939 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡